Hypothesis Tissue‑specific variations in chondroitin sulfate (CS) and heparan sulfate (HS) sulfation patterns act as metabolic gauges that regulate heparanase (HPSE) activity, thereby modulating extracellular matrix (ECM) stiffness and feeding back to drive cellular senescence.

Mechanistic Rationale

1. GAG sulfation as a nutrient sensor – High‑sulfinated HS chains bind fibroblast growth factors (FGFs) and insulin‑like growth factor‑1 (IGF‑1) with greater affinity, sequestering them from receptors. When systemic insulin/IGF signaling declines with age, the relative abundance of low‑sulfinated HS rises, freeing growth factors to activate downstream pathways that up‑regulate HPSE transcription (1).
2. HPSE‑mediated ECM remodeling – Increased HPSE cleaves HS side‑chains, reducing HS‑dependent cross‑linking with collagen and elastin, which lowers tensile strength but simultaneously exposes cryptic collagen cross‑linking sites that promote lysyl oxidase (LOX) activity, raising matrix stiffness (2).
3. Stiffness‑driven senescence – Elevated ECM stiffness activates integrin‑FAK‑YAP signaling in resident cells, reinforcing p16^INK4a^ expression and the senescence‑associated secretory phenotype (SASP). SASP factors further stimulate HPSE expression in neighboring stromal cells, creating a feed‑forward loop (3).
4. Tissue specificity – Differences in baseline sulfotransferase (e.g., NDST1, CHST11) expression across skin, bone marrow adipose, and perineuronal nets generate distinct sulfation signatures that dictate local HPSE responsiveness, explaining why ECM‑based biomarkers are detectable only in certain tissues (4).

Testable Predictions

• Prediction 1: In longitudinally sampled mice, skin and bone marrow will show an age‑dependent shift from high‑sulfinated to low‑sulfinated HS/CS ratios that precedes measurable increases in tissue HPSE activity and ECM stiffness by ≥2 weeks.
• Prediction 2: Pharmacological inhibition of HPSE (e.g., with PI‑88) in aged mice will normalize ECM stiffness without altering bulk GAG content, thereby reducing senescence markers (p16, SASP) in skin and adipose‑derived MSCs.
• Prediction 3: Tissue‑specific overexpression of NDST1 (to boost HS sulfation) in perineuronal nets will resist age‑related stiffening and preserve plasticity, whereas the same overexpression in skin will have minimal effect due to low baseline CHST11 activity.
• Prediction 4: Exogenous young‑derived ECM supplemented with hepatocyte growth factor (HGF) will fail to rejuvenate aged cells if HPSE activity remains high, indicating that sulfation‑dependent HPSE activity is a necessary gatekeeper of ECM‑mediated rejuvenation.

Falsification Criteria

• If age‑related changes in HS/CS sulfation ratios do not correlate temporally with HPSE activity or ECM stiffness across multiple tissues, the causal link is unsupported.
• If HPSE inhibition fails to modify stiffness or senescence despite confirmed target engagement, the proposed mechanotransduction pathway is incorrect.
• If forced HS hyper‑sulfation does not alter stiffness or senescence in a tissue‑specific manner, the sulfation‑HPSE axis is not a dominant regulator.

Experimental Approach

• Perform LC‑MS/MS disaccharide mapping of HS and CS from skin, bone marrow adipose, and cortex at 3, 12, 24 months in C57BL/6 mice.
• Quantify HPSE activity using a fluorogenic substrate assay and correlate with atomic force microscopy‑derived Young’s modulus.
• Intervene with HPSE inhibitor, NDST1‑AAV, or CHST11‑CRISPRa and assess senescence via flow cytometry for p16^INK4a^ and SASP cytokine profiling.
• Use decellularized young/old ECM scaffolds in vitro to test rejuvenation of aged MSCs under conditions of HPSE modulation.

Implications Confirming that tissue‑specific GAG sulfation patterns set a metabolic threshold for HPSE‑driven ECM remodeling would reposition the extracellular matrix from a passive scaffold to an active signaling hub that translates systemic metabolic state into local mechanical cues, thereby driving the heterogeneous onset of senescence observed during aging. It's a shift that could explain why interventions targeting bulk GAG levels often fail. We don't yet know if the sulfation shift is a cause or a consequence. We can't assume that HS/CS ratios alone dictate stiffness without HPSE activity.